CAR-γδ T Cell Products

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Human γδ T cells play unique and critical roles in stress monitoring, immunity to infection, and carcinogenesis. γδ T cells have a unique advantage used in cell therapy as they can be independent of human leukocyte antigen (HLA) restriction to identify and kill transformed cells. CAR-γδ T cells that express CAR molecules that target surface antigens on tumor cells to mediate a series of tumor elimination, which will be a huge innovation in tumor therapy.

Fig.1 γδ T cell and their regulation.¹

Characterization of γδ T cells

γδ T cells are promising host cells for CAR constructs with many features:

Human γδ T cells include subsets with different tissue tropisms: Vδ1+ cells are enriched in mucosal tissues (and often predominate within carcinomas), whereas Vδ2+ cells are most abundant in the blood and lymphoid organs.
γδ T cells have prognostic value in cancer patients and are associated with favorable outcomes in many tumor types.
γδ T cells possess the anti-tumor mechanisms of αβ T cells and NK cells which are mediated by T cell receptor (TCR) and co-stimulatory signals, but also by activating NK cell receptors.
γδ T cells mostly function independently of MHC class I-mediated antigen presentation, making them more applicable for the therapy of MHC class I-deficient tumors, as well as for use in allogeneic settings.

CAR-γδ T cells for Cancer Immunotherapy

CAR-γδ T cells usually present two-fold antitumor activity after transfection which is mainly by two facets, such as not only via the endogenous γδ TCRs, but also via the CAR specificity. In general, CAR-transduced Vδ2T cells have an increased cytotoxicity efficacy target to relevant tumor cells. Activated Vδ2T cells can also act as APCs and cross-present tumor-derived antigen peptides to CD8 αβ T cells while killing tumor cells. More importantly, CAR-transduced Vδ2T cells retained the ability to cross-present tumor antigens to αβ T cells.

CAR-γδ T Cells at Creative Biolabs

With professional expertise and experience in immunotherapy discovery and development, Creative Biolabs has developed a novel CellRapeutics™ platform to support our global customers' cellular therapy research, offering comprehensive antigen-targeting CAR-γδ T cells products to accelerate and advance your programs. At the same time, we are dedicated to customizing special CAR products according to the customer's special needs. Please feel free to contact us or inquire about an appropriate product or solution for you.

Reference

Silva-Santos, B.; et al. γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat Rev Cancer. 2019, 19(7):392-404.

Associated Antigen Target

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION